BMP10: Bone morphogenetic protein 10
Required for maintaining the proliferative activity of embryonic cardiomyocytes by preventing premature activation of the negative cell cycle regulator CDKN1C/p57KIP and maintaining the required expression levels of cardiogenic factors such as MEF2C and NKX2-5.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on BMP10, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Dalantercept | Phase 3 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Protein or peptide | InhibitorBone morphogenetic protein 10 inhibitor | 0 |
- Atrial fibrillation0.12
- Dilated cardiomyopathy0.09
- Ischemic stroke0.08
- Sign or symptom0.08
- Hypertrophic cardiomyopathy0.08
- Endometrial carcinoma0.08
- Rare familial disorder with hypertrophic cardiomyopathy0.08
- Renal cell carcinoma0.07
- Primary peritoneal carcinoma0.07
- Head and neck squamous cell carcinoma0.07
- Fallopian tube carcinoma0.07
- Left ventricular noncompaction0.07
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3713453, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt O95393, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets